Mayo Clinic

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Mayo Clinic

  Rochester, Minnesota 55905

  737 trials

• Mayo Clinic in Rochester

  Rochester, Minnesota 55905

  696 trials

• Mayo Clinic - Rochester

  Rochester, Minnesota 55905

  270 trials

• Mayo Clinic

  Jacksonville, Florida 32224

  145 trials

• Mayo Clinic

  Phoenix, Arizona 85259

  60 trials

• Mayo Clinic

  Scottsdale, Arizona 85259

  50 trials

• Mayo Clinic in Rochester, Minnesota

  Rochester, Minnesota 55905

  15 trials

• Mayo Clinic, Rochester, MN

  Rochester, Minnesota 55905

  7 trials

• Mayo Clinic - PIN

  Rochester, Minnesota 55905-0001

  6 trials

• The Mayo Clinic

  Rochester, Minnesota 55905

  5 trials

• Mayo Clinic - Children's Center - Rochester

  Rochester, Minnesota 55905-0001

  4 trials

• Mayo Clinic (Data Collection Only)

  Rochester, Minnesota 55905

  4 trials

• Mayo Clinic - PPDS

  Rochester, Minnesota 55905

  3 trials

  • NCT07015190Neoadjuvant Darovasertib in Primary Uveal Melanoma

    Contact: Lauren Dalvin, MD Principal Investigator

  • NCT06366464A Study of Pitolisant in Patients With Prader-Willi Syndrome

    Contact: Brittany Kehoe

  • NCT02932410A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

• Mayo Clinic - Rochester Minnesota

  Rochester, Minnesota 55905

  3 trials

  • NCT06668493Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

    Contact: Ferring Pharmaceuticals

  • NCT06510374Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Contact: Ferring Pharmaceuticals

  • NCT06026332ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

• Mayo Clinic- Site Number : 8400111

  Rochester, Minnesota 55905

  3 trials

  • NCT06372145A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  • NCT04411641Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  • NCT04458051Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

• Mayo Clinic, Merz Investigational Site #0010212

  Rochester, Minnesota 59505

  2 trials

  • NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

  • NCT07018700A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

• #1016, Mayo Clinic

  Rochester, Minnesota 55902

  1 trial

  • NCT04855656Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

    Contact: Debiopharm International S.A

• Mayo Clinic

  Florida City, Florida 32224

  1 trial

  • NCT07235293A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

    Contact: Conor O'Donnell, Dr (principal investigator)

• Mayo Clinic

  Jascksonville, Florida 32224

  1 trial

  • NCT06891755Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

    Contact: John Hatzimouratides

• Mayo Clinic

  Pheonix, Arizona 85054

  1 trial

  • NCT04871282A Study of AL102 in Patients With Progressing Desmoid Tumors

• Mayo Clinic, 1216 Second Street SW

  Rochester, Minnesota 55905

  1 trial

  • NCT07656259COMPARE-VENT Feasibility Pilot Study

    Contact: Garima Dahiya

• Mayo Clinic, 200 First Street SW

  Rochester, Minnesota 55905

  1 trial

  • NCT04127578Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

• Mayo Clinic - Accepting Adult Patients

  Rochester, Minnesota 55902

  1 trial

  • NCT06154252RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

    Contact: Bridget Neja

• Mayo Clinic - Appendix A & B

  Rochester, Minnesota 55905

  1 trial

  • NCT06305780RECOVER-AUTONOMIC Platform Protocol

• Mayo Clinic - Cancer Center - Rochester - PPDS

  Rochester, Minnesota 55905

  1 trial

  • NCT04776018A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

• Mayo Clinic, Cardiovascular Research

  Rochester, Minnesota 55905

  1 trial

  • NCT06212466MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

• Mayo Clinic, Clinical Trials Referral Office

  Rochester, Minnesota 55905

  1 trial

  • NCT06533579Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    Contact: Allen Reha

• Mayo Clinic (Data Collection and Data Analysis)

  Rochester, Minnesota 55905

  1 trial

  • NCT04291612Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

    Contact: Nadeem Abu-Rustum, MD

• Mayo Clinic, Department of Ophthalmology

  Rochester, Minnesota 55905

  1 trial

  • NCT05537220Oral N-acetylcysteine for Retinitis Pigmentosa

• Mayo Clinic Division of Nursing

  Rochester, Minnesota 55905

  1 trial

  • NCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease

    Contact: Pam Peterson

• Mayo Clinic, Division of Pulmonary and Critical Care Medicine

  Rochester, Minnesota 55905

  1 trial

  • NCT04905693Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

• Mayo Clinic: Division of Rheumatology

  Rochester, Minnesota 55905

  1 trial

  • NCT07103746Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

    Contact: Jeffery Laivell

• Mayo Clinic in Rochester, Minnesota (Site 0091)

  Rochester, Minnesota 55905

  1 trial

  • NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    Contact: Study Coordinator

• Mayo Clinic in Rochester, Minnesota (Site 0131)

  Rochester, Minnesota 55905

  1 trial

  • NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

• Mayo Clinic in Rochester, Minnesota (Site 0147)

  Rochester, Minnesota 55905

  1 trial

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Mayo Clinic in Rochester, Minnesota (Site 5024)

  Rochester, Minnesota 55905

  1 trial

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• Mayo Clinic in Rochester - Minnesota- Site Number : 8400004

  Rochester, Minnesota 55905

  1 trial

  • NCT06630806A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

• Mayo Clinic in Rochester - Minnesota- Site Number : 8400005

  Rochester, Minnesota 55905

  1 trial

  • NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

• Mayo Clinic in Rochester - Minnesota- Site Number : 8400008

  Rochester, Minnesota 55905

  1 trial

  • NCT06191315Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

• Mayo Clinic in Rochester - Minnesota- Site Number : 8400019

  Rochester, Minnesota 55905

  1 trial

  • NCT07088068A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

• Mayo Clinic in Rochester - Minnesota- Site Number : 8400049

  Rochester, Minnesota 55905

  1 trial

  • NCT06557772A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

• Mayo Clinic in Rochester - Minnesota- Site Number : 8400057

  Rochester, Minnesota 55905

  1 trial

  • NCT06676319Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

• Rochester

  Rochester, Minnesota 55905

  1 trial

  • NCT07007962Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

• Mayo Clinic Mayo Rochester

  Rochester, Minnesota 55905

  1 trial

  • NCT04417621Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

• Mayo Clinic - Minnesota /ID# 256051

  Rochester, Minnesota 55905

  1 trial

  • NCT04704921Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

• Mayo Clinic - Minnesota /ID# 263977

  Rochester, Minnesota 55905

  1 trial

  • NCT07007065Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

• Mayo Clinic (MN)

  Rochester, Minnesota 55905

  1 trial

  • NCT02052778A Study of TAS-120 in Patients With Advanced Solid Tumors

• Mayo Clinic of Rochester Site Number : 8400003

  Rochester, Minnesota 55905

  1 trial

  • NCT04401020First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

• Mayo Clinic - Oncology

  Rochester, Minnesota 55905

  1 trial

  • NCT03972488Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

• Mayo Clinic, Patient Location

  Rochester, Minnesota 55905

  1 trial

  • NCT03391466Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

• Mayo Clinic - PPDS- Site Number : 8400035

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT05911763A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

• Mayo Clinic - Rochester, Department of Oncology

  Rochester, Minnesota 55905

  1 trial

  • NCT04919226Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

• Mayo Clinic - Rochester /ID# 116899

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

• Mayo Clinic - Rochester /ID# 147304

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT02632175Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

• Mayo Clinic - Rochester /ID# 149245

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

• Mayo Clinic - Rochester /ID# 149894

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT02782663A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

• Mayo Clinic - Rochester /ID# 151681

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• Mayo Clinic - Rochester /ID# 163086

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

• Mayo Clinic - Rochester /ID# 164691

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03345823A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

• Mayo Clinic - Rochester /ID# 200455

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

• Mayo Clinic - Rochester /ID# 201091

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03539744A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

• Mayo Clinic - Rochester /ID# 215603

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• Mayo Clinic - Rochester /ID# 223506

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

• Mayo Clinic - Rochester /ID# 238683

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT03933735A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

• Mayo Clinic - Rochester /ID# 242844

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT05308654A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

• Mayo Clinic - Rochester /ID# 246228

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT06158841Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

• Mayo Clinic - Rochester /ID# 251164

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT05650632A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

• Mayo Clinic - Rochester /ID# 255258

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT06158854A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

• Mayo Clinic - Rochester /ID# 256594

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

• Mayo Clinic - Rochester /ID# 257301

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

• Mayo Clinic - Rochester /ID# 258295

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT05407636Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

• Mayo Clinic - Rochester /ID# 258402

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

• Mayo Clinic - Rochester /ID# 262807

  Rochester, Minnesota 55905-0001

  1 trial

  • NCT06223516Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

• Mayo Clinic-Rochester /ID# 265550

  Rochester, Minnesota 55905

  1 trial

  • NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

• Mayo Clinic-Rochester /ID# 273508

  Rochester, Minnesota 55905

  1 trial

  • NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

• Mayo Clinic-Rochester /ID# 273606

  Rochester, Minnesota 55905

  1 trial

  • NCT06880744A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

• Mayo Clinic-Rochester /ID# 274512

  Rochester, Minnesota 55905

  1 trial

  • NCT06772623Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

• Mayo Clinic - Rochester - Neurology

  Rochester, Minnesota 55902

  1 trial

  • NCT05686070A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

• Mayo Clinic - Rochester (Site 0073)

  Rochester, Minnesota 55905

  1 trial

  • NCT06312137A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    Contact: Study Coordinator

• Mayo Clinic - Rochester (Site 0138)

  Rochester, Minnesota 58905

  1 trial

  • NCT03162536A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

• Mayo Clinic - Rochester (Site 0148)

  Rochester, Minnesota 55905

  1 trial

  • NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Contact: Study Coordinator

• Mayo Clinic - Rochester (Site 2706)

  Rochester, Minnesota 55905

  1 trial

  • NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

    Contact: Toll Free Number

• Mayo Clinic - Rochester - Site #332

  Rochester, Minnesota 55905

  1 trial

  • NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

• Mayo Clinic (Site 0026)

  Rochester, Minnesota 55905

  1 trial

  • NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

• Mayo Clinic- Site Number : 14

  Rochester, Minnesota 55905

  1 trial

  • NCT00410761An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

• Mayo Clinic- Site Number : 8400010

  Rochester, Minnesota 55902

  1 trial

  • NCT06481904Registry for Stage 2 Type 1 Diabetes

• Mayo Clinic, St. Mary's Campus

  Rochester, Minnesota 55902

  1 trial

  • NCT05301335Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

• Mayo Clinic - Transplant Center - Rochester

  Rochester, Minnesota 55905

  1 trial

  • NCT05651932A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    Contact: Thomas Nelson